



COMPANY OVERVIEW

Titan is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides the potential for an efficacy and/or safety benefit. Titan's lead product in development is an implant for the treatment of moderate-to severe-chronic pruritus.

RECENT NEWS

[Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement](#)

Oct 12 2021, 8:00 AM EDT

[Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus](#)

Jun 23 2021, 8:00 AM EDT

STOCK OVERVIEW

| | |
|---------------|---------|
| Symbol | TTNP |
| Exchange | Nasdaq |
| Market Cap | |
| Last Price | \$ |
| 52-Week Range | \$ - \$ |

INVESTOR RELATIONS

Stephen Kilmer
T: 650-989-2215
skilmer@titanpharm.com

MANAGEMENT TEAM

Marc Rubin, MD

Executive Chairman

Kate Beebe DeVarney, Ph.D.

President and Chief Operating Officer

TITAN PHARMACEUTICALS, INC.

400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080-1958
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.